FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:766-768 September 6, 2001 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: As Wood (May 3 issue)¹ points out, individual and racial differences in the responses to drugs are increasingly often shown to reflect, at least in part, varying distributions of polymorphisms in drug receptors or drug-metabolizing enzymes among different populations. In several instances, a lesser response was found in nonwhite patients than in white patients to such drugs as the angiotensin-converting–enzyme (ACE) inhibitor enalapril, as reported by Exner et al. (May 3 issue),² and the beta-blocker bucindolol.³ These findings are valuable for guiding clinical practice.

From another perspective, it would be interesting to examine to what extent the . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.